Nocistatin: natural pain-modulating brain peptide
A naturally occurring peptide in the nervous system that counteracts a pain-amplifying signal, reducing abnormal touch sensitivity; studied only in animals, not yet tested in humans.
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
A chemistry service or a researcher ordered the sequence, it was manufactured, and mass spectrometry confirmed the right molecule was produced.
A binding or activity measurement confirmed that it actually does what the computer predicted — or didn't.
Snapshot
Class: Endogenous neuropeptide (counter-regulatory to nociceptin/orphanin FQ)
Evidence tier: Animal-only evidence
Status: No human clinical efficacy evidence identified in available literature
Best-supported effect: Attenuation of nociceptin-induced allodynia and hyperalgesia in rodent spinal models
Main caveat: No human trials; receptor target not fully characterized; no therapeutic development program
What this is
Nocistatin (NST) is an endogenous neuropeptide processed from prepronociceptin (PNOC), the same precursor protein that produces nociceptin/orphanin FQ (N/OFQ). The peptide was identified in 1998 as a bioactive fragment with functionally opposing effects to nociceptin despite sharing a common origin. Species-specific processing yields different lengths: bovine nocistatin is a 17-residue peptide, while human nocistatin is typically a 30-residue peptide. The peptide is used exclusively as a research tool and has never entered clinical development or been sold as a therapeutic.
Evidence map
| Evidence layer | Grade | What it supports |
|---|---|---|
| Human | None | No human trials or safety studies; never administered clinically |
| Animal | Moderate | Rodent intrathecal and intracerebroventricular studies show anti-allodynic and anti-hyperalgesic effects; modulation of spinal inhibitory transmission; effects on learning and anxiety in limited studies |
| In vitro | Moderate | Binding studies indicate distinct G-protein-coupled receptor; nanomolar affinity; pertussis-toxin-sensitive; does not bind NOP receptor |
| Computational | None | Not described in source |
| Mechanism | Plausible | Counter-regulatory relationship with nociceptin via distinct receptor; proposed modulation of spinal glycinergic and GABAergic transmission |
Claim check
| Claim | Verdict | Evidence layer | Confidence |
|---|---|---|---|
| Blocks nociceptin-induced allodynia and hyperalgesia | Supported (animal) | Animal | Medium — rodent spinal models; limited replication across wider pain field |
| Acts through a receptor distinct from NOP receptor | Supported (in vitro) | In vitro | Medium — binding data support distinct site; target not cloned or broadly validated |
| Modulates spinal glycinergic and GABAergic transmission | Supported (animal) | Animal | Low — proposed mechanism; direct evidence not detailed in available literature |
| Therapeutic candidate for human pain disorders | Not established | None | High confidence in verdict — no human trials or development program exists |
| Peripheral routes establish central bioavailability in humans | Not established | None | High confidence in verdict — all published work uses intrathecal/intracerebroventricular routes |
Experimental exposure
This section reports exposure used in animal experiments. It does not establish human dosing.
| Context | System | Experimental exposure | Duration | Endpoint | Limitation |
|---|---|---|---|---|---|
| Rodent spinal pain model | Rats and mice | Intrathecal or intracerebroventricular injection; dose not standardized across studies | Single injection to repeated dosing (details not specified) | Nocistatin-induced blockade of nociceptin allodynia; thermal hyperalgesia; mechanical withdrawal thresholds | Central nervous system route only; effects on peripheral administration unknown |
| Spinal neurotransmission | Rodent spinal cord | Direct spinal injection; specific dose ranges not extracted | Acute timepoints | Glycine and GABA release modulation | No systemic exposure data; translation to human neuropharmacology uncertain |
| Hippocampal and behavioral | Rodent brain | Intracerebroventricular injection | Acute to repeated (details not extracted) | Spatial learning, long-term potentiation, anxiety-related behavior | Mixed results across studies; no consistent dose-response established |
Preclinical safety signals
No adverse event data are reported in the available literature for any dose, route, or species. Research-chemical products purporting to be nocistatin carry the standard risks of unverified identity, purity, and sterility. The receptor target's incomplete characterization limits ability to assess off-target or species-specific toxicological risk.
Mechanism
Nocistatin is proteolytically released from prepronociceptin at paired basic residues. The mature peptide (17 residues in bovine, 30 residues in human) is conserved at its C-terminal hexapeptide (Glu-Gln-Lys-Gln-Leu-Gln; EQKQLQ), which is sufficient to recapitulate most biological effects in assays.
The primary mechanism of action is antagonism of nociceptin/orphanin FQ at the spinal and supraspinal level, but through a distinct receptor. Where nociceptin acts via the NOP receptor to increase pain sensitivity, nocistatin acts through a separate, unidentified G-protein-coupled site. Radioligand binding studies indicate a nanomolar-affinity target sensitive to pertussis toxin and coupled to inhibition of cAMP accumulation. The molecular identity of this target has not been established, remaining a significant gap in the nocistatin literature.
The proposed spinal mechanism involves modulation of glycinergic and GABAergic inhibitory interneuron transmission. Nociceptin increases inhibitory transmission in ways that paradoxically generate allodynia; nocistatin counter-regulates this effect. Beyond pain modulation, nocistatin has been studied for effects on hippocampal long-term potentiation, learning, and anxiety-related behavior, with mixed results sensitive to dose, route, and behavioral paradigm.
Chemistry
| Field | Value |
|---|---|
| Sequence (bovine) | 17 amino acids (exact sequence not provided in source) |
| Sequence (human) | 30 amino acids (exact sequence not provided in source) |
| Active core | C-terminal hexapeptide: EQKQLQ |
| Topology | Linear peptide |
| Source | Endogenous; derived from prepronociceptin (PNOC gene product) |
| Sequence confidence | Needs review — bovine and human lengths stated; full sequences not extracted in available literature |
Open questions
- Receptor identification: The nocistatin receptor has not been cloned, broadly validated, or assigned a recognized molecular name — the most significant gap in the field and a barrier to therapeutic development.
- Replication and generalizability: Core rodent pain literature is concentrated in a small number of laboratories; broader replication across the wider pain research community is limited.
- Human translation: Whether rodent spinal pain-modulatory effects translate to human tissue, pharmacology, or clinical efficacy is entirely uncharacterized.
- Peripheral bioavailability: All published work uses direct central administration (intrathecal or intracerebroventricular); systemic pharmacokinetics, blood-brain-barrier penetration, and peripheral route efficacy are unknown.
- Therapeutic tractability: Without a defined receptor target, whether counter-regulation of nociceptin or modulation of spinal inhibitory transmission is feasible as a drug mechanism remains speculative.
Research directions for this peptide, selected from the current sources — hypotheses you can explore and model. None of it is proven yet; tap any one to see the full thinking.
Does nocistatin work by slipping inside spinal cord nerve cells and binding a protein there, rather than docking on the outside of the cell like most pain drugs do?
If true, this would point to an entirely new way of targeting pain, one that bypasses the opioid receptors that cause addiction and side effects, potentially leading to non-addictive pain treatments for chronic pain patients.
Does nocistatin's negatively charged middle region allow it to hold pain-sensing channels closed normally, but let them open precisely when tissue damage makes the environment acidic?
If true, this would reveal why pain during injury feels so much worse than background pain, and could guide development of drugs that mimic nocistatin to keep the pain gate closed even in acidic injury environments, reducing the intensity of acute injury pain.
Could swapping just three similar amino acids in the middle of nocistatin prevent it from clumping together, making it last longer and work better as a spinal cord pain treatment?
Chronic pain patients who need spinal injections require drugs that remain active for days or weeks. If a simple three-residue substitution converts nocistatin from a peptide that rapidly aggregates to one that stays stable and active, it could become a practical non-opioid option for treating severe refractory pain.
Does the extra length of human nocistatin compared to the animal version make a critical difference for its ability to modulate memory and learning in humans?
If the full human form is required for cognitive effects, researchers may have been studying the wrong version of the peptide for years. Correcting this could accelerate development of non-opioid treatments for memory-related conditions including Alzheimer's disease and PTSD.
▸full evidence table2 metrics
| metric | value | tool |
|---|---|---|
| ipTM | 0.41343727707862854 | openfold3-mlx |
| ranking score | 0.5552046895027161 | openfold3-mlx |
▸structural qualityopenfold3
| metric | value | note |
|---|---|---|
| gpde | 0.620 | global PDE — lower = better |
| disorder | 0.134 | fraction disordered |
| chain pair ipTM (A, B) | 0.413 | interface quality |
▸3-letter notation
▸recipeopenfold3-mlx 0.3.1
| parameter | value |
|---|---|
| model | openfold3-mlx 0.3.1 |
| weights | — |
| hardware | — |
| mlx version | — |
| python | — |
| random seed | — |
| msa strategy | — |
| diffusion samples | 1 |
| runtime | 86s |
| predicted by | mlx@peptide |
| predicted at | 2026-05-03 |
▸citationbibtex
@peptide{pep10965,
sequence = {MQFSEQNRQQQEPTEY},
target = {neuroprotective},
author = {peptidemodel},
year = {2026},
status = {computed}
}